BRIEF

on Integrated BioPharma, Inc. (NASDAQ:INBP)

Integrated BioPharma Reports Fiscal Year 2025 Results

Integrated BioPharma, Inc. (OTCQX:INBP), a company engaged in manufacturing and distributing nutritional products, has released its financial outcomes for the quarter and fiscal year ended June 30, 2025. The company's revenue for the quarter was $14.2 million, marking an 11.8% increase compared to the previous year’s $12.7 million. Operating income also rose to $589,000 from $402,000.

Over the fiscal year, revenue reached $54.3 million, an 8% increase from the previous year's $50.3 million. Operating income for the year was roughly $0.6 million, doubled from previous year's $0.3 million. The company posted a net income of $808,000, a significant rise from $112,000 in the prior year.

Despite a quarterly net loss of $0.2 million, the overall fiscal year performance was positive, driven largely by a core focus on its Contract Manufacturing Segment.

R. E.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Integrated BioPharma, Inc. news